For patients with symptomatic disorder necessitating therapy, ibrutinib is usually advisable based upon 4 stage III randomized clinical trials evaluating ibrutinib with chlorambucil monotherapy106 and other usually used CIT mixtures, namely FCR, bendamustine in addition rituximab and chlorambucil furthermore obinutuzumab (ClbO).107–109 Ibrutinib